報價延遲最少15分鐘:2025/03/28 08:24 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.28 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.35/-3.10
|
|
企業價值
539.04M
|
| 資產負債 |
|
每股賬面淨值
5.56
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
32.33M
|
|
每股收益
0.09
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 08:24 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations. |